On March 21, 2024 HiFiBiO Therapeutics, a leading clinical stage global biotechnology company committed to advancing patient outcomes through single-cell precision, reported its participation in the AACR (Free AACR Whitepaper) 2024 meeting, scheduled to take place April 5-10, 2024, in San Diego, CA (Press release, HiFiBiO Therapeutics, MAR 21, 2024, View Source [SID1234641326]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
On Tuesday, April 9th, Dr. Jack Russella-Pollard will present an innovative Artificial Intelligence/Machine Learning (AI/ML)-guided approach designed to seamlessly integrate single-cell data across platforms at scale. The next day, Dr. Jinping Gan will showcase PK/PD models that integrate drug properties and tumor growth characteristics, providing biologically insightful stimulations.
By harnessing these cutting-edge technologies and tools, HiFiBiO Therapeutics is steering the development of its drug candidates, including two antibodies currently undergoing Phase 1 evaluation: a first-in-class TNFR2 agonist (HFB200301, NCT05238883) and a next-generation OX40 agonist (HFB301001, NCT05229601).
These presentations underscore HiFiBiO Therapeutics’ unwavering commitment to innovation and its relentless pursuit of novel therapeutic solutions to address unmet medical needs.
Details on the poster presentations are as follows:
Abstract Number: 6202
Title: Integrating public single-cell transcriptomics and patient profiles to guide clinical development
Presenter: Jack Russella-Pollard, Ph.D., Executive Director, Translational Data Science
Session Category: Bioinformatics / Computational Biology / Systems Biology / Convergent Science
Session Title: Integrative Cancer Science
Session Date and Time: Tuesday Apr 9, 2024, 1:30 PM – 5:00 PM
Location: Poster Section 36
Poster Board Number: 5
Abstract Number: 7176
Title: Optimization of T cell co-stimulatory agonists: A semi-mechanistic PKPD model integrating drug properties and tumor-immune interactions
Presenter: Jinping Gan, Ph.D., Vice President, Global Head of Research
Session Category: Experimental and Molecular Therapeutics
Session Title: Pharmacology and Pharmacogenetics
Session Date and Time: Wednesday Apr 10, 2024, 9:00 AM – 12:30 PM
Location: Poster Section 24
Poster Board Number: 17